ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Patient Outcomes, Preferences, & Attitudes Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 0370
Adolescents’ and Providers’ Perceptions of the Transition from Pediatric to Adult Rheumatology
10:30AM-12:30PM
Abstract Number: 0369
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
10:30AM-12:30PM
Abstract Number: 0363
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
10:30AM-12:30PM
Abstract Number: 0368
Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
10:30AM-12:30PM
Abstract Number: 0362
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0373
Enhancing Lupus Patient Education and Support at Kings County Hospital
10:30AM-12:30PM
Abstract Number: 0357
Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
10:30AM-12:30PM
Abstract Number: 0364
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
10:30AM-12:30PM
Abstract Number: 0354
Factors Associated with Health Information Technology Use Among United States Adults with Arthritis from 2012-2017: Analysis of the National Health Interview Survey
10:30AM-12:30PM
Abstract Number: 0366
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
10:30AM-12:30PM
Abstract Number: 0374
How Do Patient Decision Aids Enable Purposeful Shared Decision-Making in Rheumatology? An Integrative Review
10:30AM-12:30PM
Abstract Number: 0355
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
10:30AM-12:30PM
Abstract Number: 0361
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
10:30AM-12:30PM
Abstract Number: 0367
Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
10:30AM-12:30PM
Abstract Number: 0375
Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
10:30AM-12:30PM
Abstract Number: 0356
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
10:30AM-12:30PM
Abstract Number: 0365
Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 0372
Readability Analysis of the American College of Rheumatology Patient Education Material
10:30AM-12:30PM
Abstract Number: 0358
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
10:30AM-12:30PM
Abstract Number: 0359
SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients
10:30AM-12:30PM
Abstract Number: 0371
This Is Caring: Enhancing Patient Education Materials for Individuals with Morphea Through Qualitative Inquiry
10:30AM-12:30PM
Abstract Number: 0360
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology